López-Aburto G, Palacios-Rodríguez JM, Cantú-Ramírez S, Galván GE, Tolosa-Dzul G, Morán- Benavente A, Ontiveros-Martínez R

Language: Spanish
References: 23
Page: 189-195
PDF size: 191.67 Kb.

ABSTRACT

Objective: To know the demographic, clinical, hemodynamic, and hospital course, and medium term septal obstructive hypertrophic cardiomyopathy. Material and methods: Observational, longitudinal direction retrospective, descriptive and comparative (case series), including 21 patients with septal obstructive hypertrophic cardiomyopathy with the following criteria: functional class III-IV New York Heart Association refractory to treatment and/or ≥ 30 mmHg gradient at rest or ≥ 60 mm Hg provoked, and others have systolic anterior motion or mitral insufficiency › GII this by echocardiography. Results: Demographic variables: population-average age of the cohort was 50 ± 16 years, distribution by gender: men n = 8 (38.1%), women n = 13 (61.9%) symptoms: angor n = 9 (42.9%), dyspnea n = 18 (85.7), syncope n = 5 (23.8) CF-NYHA (pre-ablation): CF3 n = 12 (57.1%), CF4 n = 1 (4.8%); drug use: BB n = 15 (71.4%), verapamil n = 13 (61.9%), ACE inhibitors n = 3 (14.3%), ECG LVH n = 17 (81%), FA n = 1 (4.8%), LBHH n = 3 (14.3%); ecocardiogaphic-eco baseline: 14.9 ± 4.4 mm WPLV, IVS 22.7 ± 4.9 mm, EF: 65.5 ± 7%, Gte.TVG: 106.9 ± 29.9 mmHg, MI-3 grade n = 7 (33.3%), grade MI-4 n = 10 (47.6%) Post-intervention-eco gte TVG 44.6 ± 24.3 mm, grade MI-3 n = 3 (14.3%), grade MI-4 n = 1 (4.8%) 3.4 ± 0.9 ml alcohol, hospital stay 5.9 ± 3 days, CPK-total 1466 ± 924; CK-MB 215 ± 128, LVB transient electrical complications n = 11 (52.9%), permanent cardiac pacemaker n = 1 (4.8)-FE hemodynamic baseline: 65.5% ± 16, post-FE 62.2% ± 6.5; Gte Basal: 106.33 ± 37 mmhg GTE-post 44 ± 34 mmHg, evolution: 1 year follow-up CF-NYHA, CF1: n = 19 (90.5%), CF2: n = 2 (9.5%); Eco Gte 22.0 ± 5.7 mm Hg LVOT, 20.7 ± 3.1 mm SIV, FE (68.7 ± 6.2%), IM-0 n = 11 (52.4%), IM-1 n = 6 (28.6%), IM-2 n = 4 (19%), hospital mortality of 0%. Conclusion: The alcohol septal ablation is a method that has a high success rate, with an improvement in the quality of life of patients with a low complication rate.

REFERENCES

1. Richardson P, McKenna W, Bristow M et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies. Circulation. 1996; 93: 841.

2. Maron BJ, Bonow RO, Cannon RO et al. Hypertrophic cardiomyopathy. Interrelations of clinical manifestations, pathophysiology, and therapy. N Engl J Med. 1987; 316: 844.

3. Maron BJ, Spirito P, Wesley Y, Arce J. Development or progression of left ventricular hypertrophy in children with hypertrophic cardiomyopathy: identification by two-dimensional echocardiography. N Engl J Med. 1986; 315: 610.

4. Charron P, Dubourg O, Desnos M et al. Clinical features and prognostic implications of familial hypertrophic cardiomyopathy related to the cardiac myosin-binding protein C gene. Circulation. 1998; 97: 2230.

5. Niimura H, Bachinski LL, Sangwatanaroj S et al. Mutations in the gene for cardiac myosin-binding protein C and late onset familial hypertrophic cardiomyopathy. N Engl J Med. 1998; 338: 1248-1257.

6. Maron BJ, Niimura H, Casey SA et al. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. J Am Coll Cardiol. 2001; 38: 315.

7. Niimura H, Patton KK, McKenna WJ et al. Sarcomere protein gene mutations in hypertrophic cardiomyopathy of the elderly. Circulation. 2002; 105: 446-451.

8. Kubo T, Kitaoka H, Okawa M et al. Lifelong left ventricular remodeling of hypertrophic cardiomyopathy caused by a founder frameshift deletion mutation in the cardiac myosin-binding protein C gene among Japanese. J Am Coll Cardiol. 2005; 46: 1737-1743.

9. Moolman JA, Reith S, Uhl K et al. A newly created splice donor site in exon 24 of the MyBP-C gene is responsible for inherited hypertrophic cardiomyopathy with incomplete disease penetrance. Circulation. 2000; 101: 1396-1402.

10. Maron BJ, Casey SA, Poliac LC et al. Clinical course of hypertrophic cardiomyopathy in a regional United States cohort. JAMA. 1999; 281: 650-655.

11. Kimmelstiel CD, Maron BJ. Role of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Circulation. 2004; 109: 452.

12. Knight C, Kurbaan AS, Seggeweiss H et al. Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy. Outcome of the first series of patients. Circulation. 1997; 95: 2075-2081.

13. Faber L, Seggewiss H, Gleichmann U. Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography. Circulation. 1998; 98: 2415-2421.

14. Gietzen FH, Leuner CJ, Raute-Kreinsen U et al. Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH). Catheter interventional treatment for hypertrophic obstructive cardiomyopathy. Eur Heart J. 1999; 20: 1342-1354.

15. Lakkis NM, Nagueh SF, Kleiman NS et al. Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy. Circulation. 1998; 98: 1750-1755.

16. Nagueh SF, Lakkis NM, Middleton KJ et al. Changes in left ventricular filling and left atrial function six months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 1999; 34: 1123-1128.

17. Flores-Ramirez R, Lakkis NM, Middleton KJ et al. Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 2001; 37: 208-214.

18. Braunwald E. Induced septal infarction: a new therapeutic strategy for hypertrophic obstructive cardiomyopathy. Circulation. 1997; 95: 1981.

19. Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet. 1995; 346: 211-214.

20. Rivera S, Sitges M, Azqueta M, Marigiliano M, Velamazán M, Miranda-Guardiola F et al. Remodelado ventricular izquierdo tras ablación septal percutánea con alcohol en pacientes con miocardiopatía hipertrófica obstructiva. Rev Esp Cardiol. 2003; 56: 1174-1181.

21. Shamim W, Yousufuddin M, Wang D, Henein M, Seggewiss H, Flather M et al. Nonsurgical reduction of the interventricular septum in patients with hypertrophic cardiomyopathy. N Engl J Med. 2002; 347: 1326-1333.

22. Lakkis N. New treatment methods for patients with hypertrophic obstructive cardiomyopathy. Curr Opin Cardiol. 2000; 15: 172-177.

23. Gietzen F, Leuner C, Gerenkamp T, Kuhn H. Relief of obstruction in hypertrophic cardiomyopathy by transient occlusion of the first septal branch of the left coronary arter [resumen]. Eur Heart J. 1994; 15: 125.